Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Accounts receivable (Details)

v3.24.3
Summary of Significant Accounting Policies - Accounts receivable (Details)
9 Months Ended
Sep. 30, 2024
USD ($)
segment
customer
Dec. 31, 2023
USD ($)
Accounts receivable    
Accounts receivable $ 12,500,000 $ 821,000
Allowance for doubtful accounts $ 0  
Number of reportable segments | segment 1  
Customer Concentration Risk    
Accounts receivable    
Accounts receivable $ 12,500,000 $ 821,000
Customer Concentration Risk | Genentech, Inc.    
Accounts receivable    
Accounts receivable $ 0  
Customer Concentration Risk | Genentech and GSK Customers    
Accounts receivable    
Number of customers | customer 3